The Outcomes of Respiratory Support and Anti-Covid Therapy on Covid-19 Patients in the Special Isolation Room – Intensive Care Unit at Dr. Soetomo General Hospital

An ongoing research of therapy COVID-19 has different outcomes, especially in critical care. We aimed to described outcomes of respiratory support and anti-COVID combination on COVID-19 patient in intensive care unit. Methods: This single-centered, retrospective, observational study, we enrolled 68 critically ill who were admitted to the Intensive Care Unit in the Special Isolation Room of Dr. Soetomo General Hospital, Surabaya between May-October 2020. Demographic data, respiratory support, anti-COVID, length of stay and mortality were all collected through medical record. Results: A total 68 patient were included. The mean age of the patients was 49.19 years (SD 11.05), 19 (27.9%) were men, 42 (61.8 %) has chronic illness, 38 (55,9%) patients had died, the median duration for admission to the intensive care unit (ICU) with survivor 9 days (IQR 6- 17). Respiratory support with HFNC were 21 patients (30.9%), Ventilator 36 patient (52,9%), combination HFNC and Ventilator 11 patients (16.2 %). Patients who received lopinavir/ritonavir were 43 (63.2 %) and hydrocloroquine 25 (36.8%.). The mean p/f ratio day 3 was 136.27 (SD 63.93), CRP 10.88 mg/L (SD 8.23), IL-6 208.79 pg/mL (SD 529.03). Compare with survivors, non survivors who recieved HFNC were 3 patients (14.3 %) vs 18 patients (85.7%), mechanical ventilator 31 patients (86.1%) vs 5 patients (13.9%), combination HFNC and mechanical ventilator 4 patients (36.4%) vs 7 patients (63.6%), within who receive HCQ mortality was 17 patients (44.7%) vs 8 patients (26.7%) and lopinavir/ritonavir 21 patients (55.7%) vs 22 patients (73.3%). Conclusion: The mortality of COVID-19 patients in ICU is considerable. Patients who receive HFNC has better outcome and lower mortality because of lower degree of disease severity. A further large-scale, prospective, and multicenter study is necessar